Al-Ola A Abdallah, Director of Plasma Cell Disorders Care at The University of Kansas Health System and Chair of USMIRC, shared on X:
“Four more ASH26 abstracts I’m watching beyond my top 11, each exploring a new role for CAR-T or T-cell engagers in myeloma or AL amyloidosis. Here’s what caught my eye.
1. IMMUNOPLANT
Can short-course linvoseltamab help patients defer upfront ASCT? Among 37 who remained MRD-positive after induction and completed 4 cycles, 86.5% reached MRD negativity at 10⁻⁶. I’m watching 2-year PFS. A randomized ASCT comparison is still needed.
2. TRIgnite-1
What works after BCMA therapy? With ABBV-2001, a CD38×BCMA×CD3 trispecific, 77% of evaluable patients previously treated with BCMA CAR-T or a T-cell engager responded. I want to see response duration broken down by which BCMA therapy patients received.
3. QI-019A
In vivo CD19/BCMA CAR-T without ex vivo manufacturing or lymphodepletion. Median screening to infusion was 8 days. Six of 8 evaluable patients responded, including 4 stringent CRs. With 9 treated and 2 months’ median follow-up, durability and late toxicity matter
4. Frontline teclistamab in stage IIIB AL amyloidosis
Median time to first response was 13 days. Yet 8/24 patients died, 6 from heart failure. The question I’d ask at ASH: does rapid light-chain suppression improve 3- and 6-month survival across all enrolled patients?”
About ASH 2026
The American Society of Hematology (ASH) Annual Meeting and Exposition is one of the world’s leading events in hematology, bringing together physicians, researchers, and healthcare professionals to discuss the latest advances in blood cancer research and the treatment of blood disorders.
ASH 2026 will highlight new clinical trial results, emerging therapies, and scientific developments across hematology, with particular attention to multiple myeloma, leukemia, lymphoma, and other blood-related diseases.
The 68th ASH Annual Meeting will take place December 12-15, 2026, in New Orleans, Louisiana, with a virtual attendance option. It is expected to bring together more than 30,000 participants and feature thousands of scientific abstracts.
You may also be interested in:
- Al-Ola A Abdallah: A Remarkable Outcome in Penta-Refractory Myeloma After Just One Dose of Belantamab
- Al-Ola A. Abdallah: 11 Key Abstracts to Watch at ASH 2026
- Luciano Costa Shares His Top 10 Multiple Myeloma Abstracts at ASH 2026